New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting
CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Cytogen Corporation(NASDAQ: CYTO) today reported results from clinical trialsdemonstrating that QUADRAMET (samarium Sm-153 lexidronam injection)can be safely administered to prostate cancer patients who are alsoreceiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis).Clinical data also support further evaluation of the combinationregimen for...